Screener
USANA Health Sciences USNA Rise — Operating Income (Loss)
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by USANA Health Sciences in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: USANA Health Sciences’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:35 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000896264-26-000034
| Line item | Core Nutritional | Hiya | Rise | Total |
|---|---|---|---|---|
| Cost of sales | 36,749 | 9,983 | 12,704 | 59,436 |
| Brand Partner incentives | 88,654 | — | — | 88,654 |
| Selling, general and administrative (2) | 60,747 | 24,771 | 2,736 | 88,254 |
| Segment earnings (loss) from operations | $18,249 | $(2,604) | $(1,771) | $13,874 |
| Reconciliation of segment earnings from operations | ||||
| Interest income | 437 | |||
| Interest expense | (240) | |||
| Other, net | 1,394 |
Item 1. FINANCIAL STATEMENTS
FAQ
- What is USANA Health Sciences's rise — operating income (loss)?
- USANA Health Sciences (USNA) reported rise — operating income (loss) of -$1.77M in Q1 2026.
- What does rise — operating income (loss) mean?
- Calculated as the net sales of the Rise segment minus its cost of sales, brand partner incentives, and allocated operating expenses. This metric serves as the primary indicator of the segment's core operational profitability and financial health.
Ask your AI about USANA Health Sciences's rise — operating income (loss).
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude